← Therapeutics
Details checkedClinical trial listing onlyHistorical/discontinuedCheckedregistry
Moberly intratympanic dexamethasone cisplatin-otoprotection study
Also known as: Dexamethasone in preventing hearing loss in patients receiving cisplatin, NCT02382068
Investigator-led study
Sponsor / Institution
Investigator-led study
Program Type
Therapeutic
Modality
Steroid/Anti-inflammatory
Stage
Interventional/NA
Status
Discontinued
Target Gene
—
Route / Mode
Intratympanic injection
Confidence
70%
Status Confidence
Status needs checking
Evidence Strength
Needs more support
Last Reviewed
2026-06-10
Geography
United States
Population
adult, cisplatin-ototoxicity, study-level
Trial IDs
1
Mechanism
Withdrawn investigator-led pilot trial of intratympanic dexamethasone in one ear versus placebo in the other ear during cisplatin standard-of-care treatment to assess otoprotection.
Indications
Notes
Split out from the broad dexamethasone cluster. ClinicalTrials.gov verifies a withdrawn investigator-led cisplatin otoprotection pilot; this should be interpreted as historical registry evidence for generic intratympanic steroid use.
Evidence & Sources
1 structured sourcesclinicaltrials
Supports: canonicalName, aliases, company, allCompanies, isIndustrySponsored, programType, modality, mechanism...
IDs: NCT02382068
Key Events
Clinical Trials (1)
Data Checks
investigator-led-studyregistry-verified-studydiscontinued-registry-studygeneric-drug-studystudy-level-not-standalone-productnot-commercial-pipeline-program
Related Programs
Otarmeni by Regeneron
Company: Regeneron Pharmaceuticals · Gene Therapy · Approved
PEDMARK by Fennec Pharmaceuticals
Company: Fennec Pharmaceuticals · Small Molecule · Marketed
AK-OTOF by Eli Lilly and Akouos
Company: Eli Lilly and Company · Gene Therapy · Phase 2
SENS-401 (Arazasetron) by Sensorion
Company: Sensorion · Small Molecule · Phase 2
SENS-501 by Sensorion
Company: Sensorion · Gene Therapy · Phase 1/2
Rincell-1 by Rinri Therapeutics
Company: Rinri Therapeutics · Cell Therapy · Phase 1/2